Support: Roche, Stockholm County Council Speaking and Teaching: MSD/SP, Karin Lindahl ‐ Advisory Committees or Review Panels: Abbvie Grant/Research Also treatment for CHC improved survival for CHC patients on HD. Discussion The result from this nationwide registry study showed CHC patients to be at higher risk of developing CKD. The hazard ratio for not receiving CHC treatment adjusted for age at HD and kidney transplantation was 2.84 (1.52‐5.39). A multivariate regression analysis showed CHC treatment, kidney transplantation, and younger age at first HD to independently be associated with better prognosis for CHC patients on HD. Overall, 17% (45/268) of the CHC patients on HD had been treated for CHC, and 24% (11/45) in the treated cohort died compared with 56% (127/223) in the untreated cohort (P<0.0001 Figure). The frequency of CHC patients on HD was 0.63% compared with 0.10% in the matched comparators. Of these were 2.5% (n=1,077) diagnosed with CKD during 280,123 PY, compared with 0.7% (n=1,454) in the matched comparators (1,504,765 PY) resulting in a standardized incidence ratio (SIR) of 4.0. Results During 20, 42,522 visited a physician with a CHC diagnosis. Follow‐up started at date of CHC diagnosis and patients accrued person‐years (PY) in until death, emigration or 31st Dec 2013, whichever came first. For each patient up to 5 non‐CHC diagnosed age/sex/place of residency‐matched comparators were drawn from the general population at time of diagnosis. Treatment (IFN/RBV) was identified using ATC codes in the Prescribed Drug Registry. HD was defined using the procedure code in the non‐primary outpatient care. Methods The patients were identified for CHC (B18.2) and CKD (N18) according to ICD‐10 in the inpatient care day surgery and non‐primary outpatient care in the nationwide Swedish Patient Register (2001‐2013). The aim of this registry study was to describe renal disease for Swedish CHC patients. Title: Higher risk of renal disease in chronic hepatitis C patients, and treatment improved survival for hemodialysis patients – A nationwide population‐based register study from 2001 to 2013Īuthors/Affiliations: Jonas Söderholm 1,2, Charlotta Millbourn 3, Katharina Büsch 1,2, Jan Kövamees 1, Robert Schvarcz 3, Karin Lindahl 3, and Annette Bruchfeld 4, 1AbbVie AB, Stockholm, Sweden, 2Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden, 3Department of Medicine, Division of Infectious Diseases, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden, 4Department of Renal medicine, CLINTEC, Karolinska Institutet, Stockholmīackground Studies have shown chronic hepatitis C (CHC) negatively impact kidney function, as well as survival for patients with chronic kidney disease (CKD) or on hemodialysis (HD). The abstract should have read as follows: In the October 2016 supplement issue of H epatology, in the section titled “Poster Session II (Abstracts 730‐1194)” (volume 64, pages 361A‐601A doi: 10.1002/hep.28798), abstract 738 was erroneously listed as “Withdrawn” on page 365A.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |